Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

EC approves Roche’s Tecentriq combo vs. lung cancer

Roche received European Commission (EC) approval for the company’s Tecentriq drug in combination with Avastin and chemo as an initial treatment for people with a specific type of lung cancer.

Read More »

More specimen sharing would yield more breakthroughs

Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.

Read More »

FDA accepts Roche’s supplemental biologics license application for Tecentriq plus chemotherapy for initial treatment of metastatic non-squamous non-small cell lung cancer

Roche announced that the U.S. Food and Drug Administration accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq in combination with Abraxane and carboplatin for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.

Read More »

Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).

Read More »

Genentech Cutting More Jobs in Bay Area

South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.

Read More »

Roche’s lung cancer combo treatment wins FDA approval

Roche Holding AG’s Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.

Read More »

FDA Approves Another Indication for Merck’s Keytruda

Merck’s blockbuster anti-PD-1 therapy Keytruda won FDA approval in combination with chemotherapy as a first-line treatment for patients with metastatic squamous non-small cell lung cancer.

Read More »

With new blood test, Roche dives deeper into personal cancer care

Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.

Read More »

Takeda lung cancer drug gets European panel nod

Takeda Pharmaceutical Co.’s lung cancer drug Alunbrig received the recommendation of a European Union panel, more than a year after winning U.S. regulatory approval.

Read More »

Celgene Ends Navicixizumab Licensing Deal with OncoMed

Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom